Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

Literature DB >> 26471485

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

Stefano Luminari¹, Sara Galimberti², Annibale Versari³, Irene Biasoli⁴, Antonella Anastasia⁵, Chiara Rusconi⁶, Angela Ferrari⁷, Mario Petrini², Martina Manni⁸, Massimo Federico⁸.

Abstract

Entities: Disease Species

Keywords: FDG-PET; follicular lymphoma; minimal residual disease; nuclear medicine; progression-free survival

Mesh：

Substances：

Year: 2015 PMID： 26471485 PMCID： PMC4938338 DOI： 10.3324/haematol.2015.132811

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

10 in total

Review 1. Follicular lymphoma: 2014 update on diagnosis and management.

Authors: Arnold Freedman
Journal: Am J Hematol Date: 2014-04 Impact factor: 10.047

2. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Authors: Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani
Journal: Blood Date: 2013-06-18 Impact factor: 22.113

3. Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3' BCL2 breakpoints and evidence of a new cluster.

Authors: G Buchonnet; P Lenain; P Ruminy; S Lepretre; A Stamatoullas; F Parmentier; F Jardin; C Duval; H Tilly; C Bastard
Journal: Leukemia Date: 2000-09 Impact factor: 11.528

4. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

Authors: Mark Roschewski; Kieron Dunleavy; Stefania Pittaluga; Martin Moorhead; Francois Pepin; Katherine Kong; Margaret Shovlin; Elaine S Jaffe; Louis M Staudt; Catherine Lai; Seth M Steinberg; Clara C Chen; Jianbiao Zheng; Thomas D Willis; Malek Faham; Wyndham H Wilson
Journal: Lancet Oncol Date: 2015-04-01 Impact factor: 41.316

5. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.

Authors: Sara Galimberti; Stefano Luminari; Elena Ciabatti; Susanna Grassi; Francesca Guerrini; Alessandra Dondi; Luigi Marcheselli; Marco Ladetto; Pier Paolo Piccaluga; Anna Gazzola; Claudia Mannu; Luigia Monitillo; Barbara Mantoan; Ilaria Del Giudice; Irene Della Starza; Marzia Cavalli; Luca Arcaini; Alessandra Tucci; Giuseppe Alberto Palumbo; Luigi Rigacci; Alessandro Pulsoni; Umberto Vitolo; Carola Boccomini; Daniele Vallisa; Giovanni Bertoldero; Gianluca Gaidano; Pellegrino Musto; Mario Petrini; Massimo Federico
Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531

6. Revised response criteria for malignant lymphoma.

Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544

7. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.

Authors: J G Gribben; D Neuberg; A S Freedman; C D Gimmi; K W Pesek; M Barber; L Saporito; S D Woo; F Coral; N Spector
Journal: Blood Date: 1993-06-15 Impact factor: 22.113

8. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.

Authors: S Luminari; I Biasoli; L Arcaini; A Versari; C Rusconi; F Merli; M Spina; A J M Ferreri; P L Zinzani; A Gallamini; S Mastronardi; C Boccomini; G Gaidano; A M D'Arco; F Di Raimondo; A M Carella; A Santoro; P Musto; M Federico
Journal: Ann Oncol Date: 2013-04-12 Impact factor: 32.976

9. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.

Authors: Massimo Federico; Stefano Luminari; Alessandra Dondi; Alessandra Tucci; Umberto Vitolo; Luigi Rigacci; Francesco Di Raimondo; Angelo Michele Carella; Alessandro Pulsoni; Francesco Merli; Luca Arcaini; Francesco Angrilli; Caterina Stelitano; Gianluca Gaidano; Matteo Dell'olio; Luigi Marcheselli; Vito Franco; Sara Galimberti; Stefano Sacchi; Maura Brugiatelli
Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544

10. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.

Authors: Judith Trotman; Stefano Luminari; Sami Boussetta; Annibale Versari; Jehan Dupuis; Christelle Tychyj; Luigi Marcheselli; Alina Berriolo-Riedinger; Antonella Franceschetto; Anne Julian; Fabien Ricard; Luca Guerra; Corinne Haioun; Irene Biasoli; Hervé Tilly; Massimo Federico; Gilles Salles; Michel Meignan
Journal: Lancet Haematol Date: 2014-09-17 Impact factor: 18.959

10 in total

11 in total

Review 1. Current challenges in the management of follicular lymphoma.

Authors: Maryam Sarraf Yazdy; Chaitra Ujjani
Journal: Int J Hematol Oncol Date: 2017-06-30

2. Evolution of lymphoma staging and response evaluation: current limitations and future directions.

Authors: Joel Cunningham; Sunil Iyengar; Bhupinder Sharma
Journal: Nat Rev Clin Oncol Date: 2017-06-13 Impact factor: 66.675

Review 3. Does MRD have a role in the management of iNHL?

Authors: Ilaria Del Giudice; Irene Della Starza; Robin Foà
Journal: Hematology Am Soc Hematol Educ Program Date: 2021-12-10

Review 4. Unmet needs in the first-line treatment of follicular lymphoma.

Authors: C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal: Ann Oncol Date: 2017-09-01 Impact factor: 32.976

5. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.

Authors: Marie-Hélène Delfau-Larue; Axel van der Gucht; Jehan Dupuis; Jean-Philippe Jais; Isabelle Nel; Asma Beldi-Ferchiou; Salma Hamdane; Ichrafe Benmaad; Gaelle Laboure; Benjamin Verret; Corinne Haioun; Christiane Copie-Bergman; Alina Berriolo-Riedinger; Philippine Robert; René-Olivier Casasnovas; Emmanuel Itti
Journal: Blood Adv Date: 2018-04-10

Review 6. The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era.

Authors: Francesco Maura; Lucia Farina; Paolo Corradini
Journal: Mediterr J Hematol Infect Dis Date: 2016-09-01 Impact factor: 2.576

7. The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.

Authors: Francesca Guerrini; Matteo Paolicchi; Francesco Ghio; Elena Ciabatti; Susanna Grassi; Serena Salehzadeh; Giacomo Ercolano; Maria R Metelli; Marzia Del Re; Lorenzo Iovino; Iacopo Petrini; Giovanni Carulli; Nadia Cecconi; Martina Rousseau; Giulia Cervetti; Sara Galimberti
Journal: Front Pharmacol Date: 2016-10-13 Impact factor: 5.810